Children are increasingly being looked at as part of the effort to widen mass COVID-19 vaccinations. Drugmaker Moderna announced it has begun studying the vaccine in children aged 6 months to 11 years in the U.S. and Canada.
The pediatric study is looking at both the safety and immune response in the younger population and is expected to help boost population-level immunity if the shots prove to be safe and effective. So far Moderna and Johnson & Johnson’s vaccines are authorized for use in adults 18 and over. Pfizer is cleared for ages 16 and up.